MedTrace Logo

TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB

NCT03251196 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2021-01-13

No results posted yet for this study

Summary

This is an observational cohort study. Pulmonary tuberculosis (TB) patients will be enrolled at the time of TB diagnosis and prospectively followed for at least two years after TB-treatment initiation with optional prolonged follow-up. Study visits will be performed in the study clinics or if necessary at the participant's home at pre-defined time points after TB treatment initiation. Clinical assessments, biological sample collections and collection of socio-economic data will be performed according to the pre-defined schedule of events.

Conditions

  • Respiratory Tract Infections
  • Tuberculosis, Pulmonary

Interventions

OTHER

No Intervention, and Observational Study

Observational Study

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    collaborator OTHER

  • Research Center Borstel

    collaborator OTHER

  • University of Witwatersrand, South Africa

    collaborator OTHER

  • Mbeya Medical Research Centre NIMR

    collaborator UNKNOWN

  • Ministry of Health Instituto Nacional de Saude

    collaborator UNKNOWN

  • Medical Research Council Unit, The Gambia

    collaborator OTHER

  • Karolinska Institutet

    collaborator OTHER

  • The Aurum Institute NPC

    lead OTHER

Principal Investigators

  • Gavin J Churchyard · Chief Executive Officers

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-22
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • Mozambique
  • South Africa
  • Tanzania
  • The Gambia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03251196 on ClinicalTrials.gov